Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DCOP72
|
|||
| Drug Name |
Nomacopan
|
|||
| Drug Type |
Recombinant protein
|
|||
| Indication | Bullous pemphigoid [ICD-11: EB41.0; ICD-10: L12.0] | Phase 3 | [1] | |
| Thrombotic microangiopathy [ICD-11: 3B65; ICD-10: M31.1] | Phase 3 | [2] | ||
| Company |
Akari Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Complement C5 (CO5) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Prion diseases | ||||
| Pertussis | ||||
| Staphylococcus aureus infection | ||||
| Herpes simplex infection | ||||
| Systemic lupus erythematosus | ||||
| Reactome | Activation of C3 and C5 | |||
| Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | ||||
| Regulation of Complement cascade | ||||
| WikiPathways | Complement Activation, Classical Pathway | |||
| Human Complement System | ||||
| Spinal Cord Injury | ||||
| Allograft Rejection | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Complement cascade | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05061771) A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical Study to Evaluate the Efficacy and Safety of Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP). U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04784455) Multicentre Study of Nomacopan (rVA576) in Paediatric Haematopoietic Stem-Cell Transplant Associated Thrombotic Microangiopathy. U.S.National Institutes of Health. | |||
| REF 3 | Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial. JAMA Dermatol. 2022 Jun 1;158(6):641-649. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.